The FDA will hold a public meeting on March 20 to discuss the use of complex innovative designs (CID) in clinical trials of drugs and biological products to inform regulatory decision making. The meeting is intended to help the FDA develop a guidance document on CID, as required by the 21st Century Cures Act, and develop a CID pilot program.  To register for this meeting, visit: https://complexinnovativedesigns.eventbrite.com/  (Regulatory Focus)